Enovix Corp (ENVX) · Nov 18, 2026 · Share issuance
$169M warrant capacity — 1 warrant per 4 shares; $3 cash or $1,000 of 2028 Notes per 333 warrants
Enovix’s warrant distribution is now live, giving holders a $3 exercise option and a way to retire 2028 notes instead of paying cash.
Enovix is shifting its near-term battery commercialization toward smart eyewear and drone applications while Fab2 remains at existing production levels; it recently disclosed an initial drone-cell purchase order for first-quarter 2027 deliveries and expects 2027 revenue of $65 million to $85 million. Against that backdrop, this filing puts the previously announced financing tool into investors’ hands rather than announcing a new operating milestone.
The important feature is the payment flexibility. Holders can exercise for cash at $3 per share, or deliver $1,000 principal amount of 2028 Notes for every 333 warrants and receive 333 shares. 〔0〕 If investors choose the note route, Enovix can reduce debt and future interest expense without spending cash; if they choose cash, the company receives new liquidity that can support operations or debt retirement. 〔1〕
| Term | Filing figure | Comparison |
|---|---|---|
| Distribution ratio (Warrant terms) | 1 per 4 shares | — |
| Cash exercise price (Warrant terms) | $3.00 | — |
| Note exercise ratio (Note Exercise Alternative) | 333 warrants | $1,000 2028 Notes |
| Early-expiration threshold (Early Expiration Price Condition) | $3.30 VWAP | 20 of 30 trading days |
This is incremental, not a surprise. Enovix had already declared the warrant dividend on October 28, and the recent quarterly filing disclosed the same core terms, including the ability to use 2028 Notes. The new information is that distribution has occurred and the mechanics are now actionable—not that the company has actually raised cash or retired debt.
The balance-sheet benefit remains contingent on investor behavior. Enovix says the amount of debt retired and cash raised will depend on how holders exercise, and the warrants can expire early if the stock meets the stated VWAP condition. That makes this a useful capital-structure option for a cash-burning commercialization story, but not yet a realized financing improvement.
Bottom line: The distribution modestly strengthens Enovix’s funding and debt-management options, but it does not yet change the operating story because no proceeds or debt retirement are locked in. It is a partly anticipated step with upside contingent on exercise participation.
Warrant exercise or early-expiration announcement
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!